替诺福韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的临床观察
发布时间：2018-10-12 11:37
【摘要】：目的:探讨复方鳖甲软肝片联合替诺福韦治疗慢性乙型肝炎肝纤维化的临床疗效。方法:收治慢性乙型病毒性肝炎肝纤维化患者96例,随机分为治疗组与对照组。对照组给予替诺福韦治疗,治疗组给予复方鳖甲软肝片联合替诺福韦治疗,比较两组HBV-DNA、Fibroscan值及肝纤维化指标。结果:两组治疗后血清HBV-DNA水平均明显低于治疗前,差异具有统计学意义(P0.05)。治疗后,两组血清HA、LN、PCⅢ、Ⅳ-C及Fibroscan值(FS)均低于治疗前,差异具有统计学意义(P0.01)。治疗组血清HA、LN、PCⅢ、Ⅳ-C及Fibroscan值(FS)下降程度均优于对照组,差异具有统计学意义(P0.01)。结论:替诺福韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的临床疗效较好,能有效抑制乙肝病毒复制,明显改善肝纤维化指标。
[Abstract]:Objective: to investigate the clinical effect of compound Biejia Ruangan tablet combined with tenofovir in the treatment of chronic hepatitis B liver fibrosis. Methods: 96 patients with chronic hepatitis B liver fibrosis were randomly divided into treatment group and control group. The control group was treated with tenofovir and the treatment group was treated with compound Biejia Ruangan tablet combined with tenofovir. The HBV-DNA,Fibroscan value and hepatic fibrosis index were compared between the two groups. Results: after treatment, the serum HBV-DNA levels in the two groups were significantly lower than those before treatment (P0.05). After treatment, the (FS) values of serum HA,LN,PC 鈪，
本文编号：2265963
[Abstract]:Objective: to investigate the clinical effect of compound Biejia Ruangan tablet combined with tenofovir in the treatment of chronic hepatitis B liver fibrosis. Methods: 96 patients with chronic hepatitis B liver fibrosis were randomly divided into treatment group and control group. The control group was treated with tenofovir and the treatment group was treated with compound Biejia Ruangan tablet combined with tenofovir. The HBV-DNA,Fibroscan value and hepatic fibrosis index were compared between the two groups. Results: after treatment, the serum HBV-DNA levels in the two groups were significantly lower than those before treatment (P0.05). After treatment, the (FS) values of serum HA,LN,PC 鈪，
本文编号：2265963
本文链接：https://www.wllwen.com/yixuelunwen/chuanranbingxuelunwen/2265963.html
最近更新
教材专著
